Imagine a nosebleed so severe that it won't stop, coming from deep in the nose where doctors can't easily reach it with traditional methods. For these frightening cases, a new review looks at a different approach: a minimally invasive procedure called endovascular treatment, where a doctor threads a tiny catheter through blood vessels to find and block the source of the bleeding. The review, which compiled and analyzed existing reports, suggests this procedure is a feasible and safe option to have in the toolkit. However, the story isn't that simple. The area where this bleeding happens is a dangerous neighborhood, full of tiny, vital connections between blood vessels. If the material used to block the bleeding vessel accidentally slips into the wrong place, it can cause a stroke or even blindness. The review stresses that this procedure absolutely requires a thorough mapping of the blood vessels first to avoid these catastrophic complications. Because this is a narrative review based on a semi-systematic search of the literature, it's summarizing what other doctors have reported, not proving that this treatment is better or worse than other approaches. It points to a potential path forward for treating these difficult cases, but one that must be walked with extreme caution.
Narrative review suggests endovascular treatment may be feasible and safe for posterior epistaxisCan a minimally invasive procedure stop severe nosebleeds safely?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
A narrative review based on a semi-systematic search examined the role of endovascular treatment in patients with posterior epistaxis. The review compared endovascular approaches to traditional management methods, though specific comparator details and primary outcomes were not reported. The main finding was that endovascular treatment appears to be a feasible and safe option, but the review did not provide specific effect sizes, absolute numbers, or statistical measures to quantify this assessment.
Regarding safety, the review noted the potential for serious complications, including stroke or blindness, from inadvertent embolization in dangerous communications around the skull base. Specific rates of adverse events, serious adverse events, or treatment discontinuations were not reported. The authors emphasized that thorough angiographic assessment is required before proceeding with endovascular treatment to identify these hazardous anastomoses.
Key limitations include the narrative and semi-systematic nature of the review; the certainty of the evidence is therefore limited. Sample size, follow-up duration, and specific study settings for the included evidence were not reported. The review's conclusions are based on association, not causation, and do not establish efficacy or superiority over traditional approaches.
For practice, the authors suggest endovascular treatment could be a viable option for posterior epistaxis and should not be reserved solely as a last resort. However, this recommendation is tempered by the evidence's narrative quality and the serious, albeit rare, risk of catastrophic neurological complications. Clinicians must weigh these potential benefits against the procedural risks and the limited comparative effectiveness data available.
View Original Abstract ↓
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Related in Dermatology
From Other Specialties
